Fondaparinux Uses
Links shared publicly online about this topic
Emisphere Technologies And Alchemia To Research An Oral Formulation Of Fondaparinux With Eligen(R) Technology
medicalnewstoday.com — “Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere'” View full resource at medicalnewstoday.com
Most Recently Shared on March 21, 2010 at 12:17 pm By:
Emisphere Technologies And Alchemia To Research An Oral Formulation Of Fondaparinux With Eligen(R) Technology http://ow.ly/16R5rF
Using Lower-Dose Heparin During Percutaneous Coronary Intervention Does Not Appear To Reduce The Risk Of Major Bleeding
medicalnewstoday.com — “Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the antic” View full resource at medicalnewstoday.com
Most Recently Shared on September 8, 2010 at 3:00 pm By:
MNT Cardiovascular Health News
Using Lower-Dose Heparin During Percutaneous Coronary Intervention Does Not Appear To Reduce The Risk Of Major Bleeding http://mnt.to/3JqF
Blocked
theannals.com — “Blocked” View full resource at theannals.com
Most Recently Shared on October 8, 2009 at 11:20 pm By:
Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues: Allison Beck Blackm.. http://bit.ly/3liqh3
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Health Feed
Heath News & Information
-
MNT Cardiovascular
The latest cardiovascular news published daily. Articles from research centers, universities and prestigious journals.
-
The Annals
The Annals of Pharmacotherapy is a peer-reviewed medical journal advancing drug therapy by publishing evidence-based pharmacy research and clinical reviews.
Advertisement
